Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Opinion & Analysis Redhill Biopharma Ltd RDHL

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib... see more

Opinion & Analysis (NDAQ:RDHL)

    RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

    Streetwise Reports November 5, 2019

    The Calandra Report: Notes from our force field

    Thom Calandra July 23, 2014

    The Calandra Report: NYC & San Francisco Hard Asset conferences call it in from the grave

    Thom Calandra July 21, 2014

    The Calandra Report: Cambodia actionable | SF, NY gold shows look dead

    Thom Calandra July 18, 2014